Research
Hormonal
Adiponectin and members of the TGF-beta superfamily (such as BMP7 and Activin B) regulate adipocyte differentiation, mitochondrial biogenesis, and energy expenditure, serving as potential pharmacotherapeutic targets for obesity.
Hormones like adiponectin and growth factors like BMP7 play key roles in regulating fat storage and energy expenditure. Research into these pathways may lead to new treatments for obesity and diabetes.
GoodQualifiesHIGH confidence
Adiponectin increases PGC-1a expression, mitochondrial biogenesis, and FAO in myocytes... BMP7 increases mitochondrial density and the expression of mitochondrial biogenesis genes... Activin B blocks lipolysis and increases triglyceride accumulation.
Why this rating
Supported by multiple studies on the effects of these proteins on adipogenesis and mitochondrial function.
Source
Mitochondrial dysfunction in obesity
Juan C. Bournat et al. · Current Opinion in Endocrinology Diabetes and Obesity · 2010
DOI 10.1097/med.0b013e32833c3026
narrative_reviewCited 476×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Excessive caloric intake and nutrient excess cause mitochondrial dysfunction in adipocytes, leading to increased reactive oxygen species (ROS) production, which in turn causes insulin resistance and lipid accumulation.Good
- Brown adipose tissue (BAT) activity, mediated by UCP1 and regulated by transcription factors like PGC-1a and PRDM16, increases energy expenditure and thermogenesis, which can mitigate obesity and improve insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →